|
|
|
|
Eli Lilly and Company (LLY) (JOBS) Gets Rights to Sell Testosterone Drug from Acrux Limited in Deal Worth up t
INDIANAPOLIS and MELBOURNE, Australia, March 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm...
|
|
|
BES: Testosterone Gel Improves Diabetes in Hypogonadal Men
Testosterone Gel Improves Diabetes in Hypogonadal Men - in , from MedPage Today NEW CME/CE TRACKER Personalize Your Medical News: CME Information Jointly Sponsored by: and MedPage Today.CREDITS Physicians: 0.25 AMA PRA Category 1 Credit(s) Family...
|
|
|
Testosterone deal a shot in the arm for biotech
MONTHS after his death, Michael Jackson has set a music-industry record, thanks to a deal between his estate and Sony that is valued at up to $US250 million ($273.7m), according to people familiar with the terms.The deal - touted by both Sony and Jackson's...
|
|
|
Testosterone deal a shot in the arm for biotech
_ Testosterone deal a shot in the arm for biotech.
|
|
|
Lilly Buys Right to Underarm Lotion for Low Sex Drive (Update3)
(Adds Eli Lilly shares in fifth paragraph.) March 16 (Bloomberg) -- Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australias Acrux Ltd.to an underarm testosterone lotion called Axiron for men with limited sex drive...
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
AXIRON NDA currently under review by U.S.FDA for the treatment of testosterone deficiency in men PR Newswire INDIANAPOLIS and MELBOURNE, Australia, March 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that...
|
|
|
Eli Lilly To Acquire Worldwode License For Acrux Testosterone Solution Axiron
Eli Lilly and Acrux have entered into an exclusive worldwide license agreement for the potential commercialisation of Acrux's experimental underarm testosterone solution (proposed tradename Axiron).The new drug application for Axiron is currently under...
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Bioavailable Testosterone Is Protective Against Alzheimer's Disease in Elderly Chinese Men: Presented at ADI
-- Bioavailable testosterone (BT) is a strong factor in decreased risk for the development of Alzheimer's disease (AD) in healthy elderly Chinese men, according to study results reported here at the 25th Conference of Alzheimer's Disease International (ADI).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Licensing AXIRON NDA currently under review by U.S.FDA for the treatment of testosterone deficiency in men INDIANAPOLIS and MELBOURNE, Australia, March 15 ...
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
INDIANAPOLIS and MELBOURNE, Australia, March 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR.AX) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux...
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
AXIRON NDA currently under review by U.S.FDA for the treatment of testosterone deficiency in men PR Newswire INDIANAPOLIS and MELBOURNE, Australia, March 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that...
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON).
|
|
|
Bioavailable Testosterone Is Protective Against Alzheimer's Disease in Elderly Chinese Men: Presented at ADI
-- Bioavailable testosterone (BT) is a strong factor in decreased risk for the development of Alzheimer's disease (AD) in healthy elderly Chinese men, according to study results reported here at the 25th Conference of Alzheimer's Disease International (ADI).
|
